Mandy Lauw: Can Reduced-Dose DOACs Be Applied to All Patients With VTE?
Mandy Lauw, Internist-hematologist at Erasmus MC, shared a post on LinkedIn about a recent article she and her colleagues co-authored, adding:
“Evidence for the efficacy and safety of doac dose-reduction for extended VTE treatment is substantial with the renove, eve and api-cat trials. But does this apply to all patients?
This short narrative review in HemaSphere Journal, written together with Marc Carrier and Saskia Middeldorp, provides some relevant insights for clinicians whether reduced-dose doacs can be uniformly applied to all patients with thrombosis and an indication for long-term anticoagulation.”
Title: Extended treatment for venous thromboembolism: Is direct oral anticoagulant dose-reduction better for all?
Authors: Mandy N. Lauw, Saskia Middeldorp, Marc Carrier
Read the Full Article on HemaSphere Journal
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 24, 2026, 06:42Deepthi Krishna: World Blood Donor Day 2026 Celebrations at Rela Hospital
-
Jun 24, 2026, 03:36Ana Pedrero Gil: A New Approach to Post-Tonsillectomy Hemorrhage
-
Jun 24, 2026, 02:59Melissa Hollo: Making Early Anemia Detection the Standard of Care
-
Jun 24, 2026, 02:51Bruno Pougault: The Thin Line Between Bleeding and Clotting
-
Jun 23, 2026, 23:30Shunsuke Iwano: PMDA Introduces Greater Flexibility for Pediatric Factor VIII and IX Development in Japan
-
Jun 23, 2026, 23:05Rounak Dubey: ISBT Academy Session on Agentic AI
-
Jun 23, 2026, 22:59Mohammed Maher Babiker: When ‘Low Platelets’ aren’t Really Low
-
Jun 23, 2026, 22:49Giovanni Merlino: Why Does Stress Hyperglycemia Worsen Stroke Outcomes?
-
Jun 23, 2026, 22:41Tareq Abadl: Coombs Test – The Key to Detecting Immune-Mediated Hemolysis